Clover Biopharmaceuticals doses first patient in Phase I study of SCB-313 in China for malignant ascites

This article was originally published here

There are now four clinical studies evaluating SCB-313 open to recruiting patients in China and Australia across three oncology indications (malignant ascites, peritoneal carcinomatosis, and malignant pleural effusions).

The post Clover Biopharmaceuticals doses first patient in Phase I study of SCB-313 in China for malignant ascites appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply